You are being redirected to the story the piece of content is found in so you can read it in context. Please click the following link if you are not automatically redirected within a couple seconds:

Prices of AIDS medicines in developing countries continue to be a concern

Author: Médecins Sans Frontières, Published on: 28 June 2005

In a new edition of a pricing guide...Médecins Sans Frontières shows that while generic production has brought down the prices of most first-line antiretrovirals (ARVs) from over $10,000 in 2000 to as little as $150 per patient in June 2005, prices of newer ARVs and formulations for children are up to 12 times higher. Yet access to newer drugs is increasingly critical as the growing number of people with HIV/AIDS currently on treatment will inevitably develop resistance to first-line treatments. [refers to concerns about high prices of some AIDS drugs produced by Abbott, GlaxoSmithKline, Gilead, Merck][Business & Human Rights Resource Centre invited the companies involved to respond to the allegations. Abbott, GlaxoSmithKline and Merck responses are below. Gilead declined to respond]

Read the full post here

Related companies: Abbott Laboratories Gilead Sciences GlaxoSmithKline Merck